Form 4: Elanco Executive Ramiro Martin Cabral Receives Stock and Option Grants
SEC Form 4 Filing
Elanco Animal Health's Executive Vice President, Ramiro Martin Cabral, was granted restricted stock units and stock options on March 3, 2025.
Summary
- On March 3, 2025, Ramiro Martin Cabral, an Executive Vice President at Elanco Animal Health, received 44,209 shares of common stock.
- These shares are in the form of restricted stock units that vest in three equal installments on March 3, 2026, March 3, 2027, and March 3, 2028.
- Cabral also received an option to purchase 92,765 shares of Elanco common stock at an exercise price of $11.31 per share.
- These options also vest in three equal installments on March 3, 2026, March 3, 2027, and March 3, 2028, and expire on March 3, 2035.
- Following these transactions, Cabral directly owns 239,629 shares of Elanco common stock and has options to purchase 92,765 shares.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The grant of stock options and restricted stock units is a standard practice and suggests confidence in the executive's ability to contribute to the company's success.
Positives
- The grant of restricted stock units and stock options aligns the executive's interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the executive.
Future Outlook
The document does not contain any specific forward-looking statements or guidance.
Industry Context
Executive compensation packages including stock options and restricted stock units are common in the animal health industry to incentivize performance and retain key personnel.
Comparison to Industry Standards
- Stock option and restricted stock unit grants are a standard component of executive compensation packages in the pharmaceutical and animal health industries.
- Companies like Zoetis and Merck Animal Health also utilize similar equity-based compensation to align executive interests with shareholder value.
- The vesting schedules are typical, designed to encourage long-term commitment and performance.
Stakeholder Impact
- The grant of equity-based compensation aims to align the executive's interests with those of the shareholders, potentially leading to increased shareholder value.
- Employees may view the executive's compensation positively, as it reflects the company's investment in its leadership.
Key Dates
| Date | Description |
|---|---|
| 03/03/2025 | Date of grant for restricted stock units and stock options. |
| 03/03/2026 | First vesting date for one-third of the restricted stock units and stock options. |
| 03/03/2027 | Second vesting date for one-third of the restricted stock units and stock options. |
| 03/03/2028 | Final vesting date for the remaining restricted stock units and stock options. |
| 03/03/2035 | Expiration date of the stock options. |
| 03/05/2025 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.